（编辑 丛可心 袁冠琳） 证券日报网讯 12月25日，爱博医疗在互动平台回答投资者提问时表示，公司股价主要受行业集采政 策、医保支出结构调整、消费市场竞争加剧及市场情绪等多重因素影响。公司管理层始终高度重视股价 表现及股东回报，未来将继续以股东利益为出发点，不断增强核心竞争力与可持续发展能力，通过多元 举措提升公司价值，切实回报股东。 ...

Group 1 - The core viewpoint is that the in vitro diagnostic industry is facing unprecedented challenges due to intensified competition and various policy reforms, including the continuous promotion of centralized procurement and the rapid implementation of DRG [2] - The company is actively optimizing human resource costs as part of its strategy to reduce expenses and enhance efficiency in response to market and policy challenges [2] - The company is committed to improving its operational performance and increasing its intrinsic value amidst the evolving industry landscape [2]

Core Viewpoint - The company, Shanghai Kehua Bio-engineering Co., Ltd., has received a stable credit rating from United Credit Ratings, despite reporting significant losses in its recent semi-annual report due to industry challenges and policy changes [2][3]. Group 1: Credit Rating - United Credit Ratings assigned an individual credit rating of a+ and a long-term credit rating of A+ to the company, with a stable outlook [2]. - The ratings for the company's issued bonds are also A+, with the ratings valid for the duration of the bonds [2]. Group 2: Financial Performance - The company reported a significant decline in revenue and gross profit, with a year-on-year decrease of 209.76% as per the semi-annual report disclosed on August 27, 2025 [2][3]. - Contributing factors to the losses include intensified industry competition due to ongoing policy reforms, leading to decreased demand for certain testing projects and a drop in product prices [3]. - The company has maintained its R&D expense ratio at the same level as the previous year and has increased marketing investments to expand its domestic and international market presence [3]. Group 3: Asset Management - The company has made provisions for impairment risks on accounts receivable, inventory, and fixed assets, which negatively impacted profits [3]. - As of June 30, 2025, the company had cash reserves of 818 million, providing a high coverage level for the "Kehua Convertible Bond" balance, indicating that the recent losses are not expected to significantly affect the long-term credit rating [3].